Cite
HARVARD Citation
Kotani, D. et al. (n.d.). 607TiPBIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). Annals of oncology. p. . [Online].